通信電纜 網絡設備 無線通信 云計算|大數據 顯示設備 存儲設備 網絡輔助設備 信號傳輸處理 多媒體設備 廣播系統 智慧城市管理系統 其它智慧基建產品
北京方程嘉鴻科技有限公司
北京方程嘉鴻科技有限公司
北京方程生物公司經營銷售毛細血管擴張性共濟失調突變基因（ATM）ELISA試劑盒，可以提供免費代測，送檢贈京東卡活動正在進行中，詳情咨詢銷售人員
PACAP
試劑盒名稱:毛細血管擴張性共濟失調突變基因(ATM)ELISA試劑盒
英文名：Human pituitary adenylate cyclase activating polypeptide,PACAP
品牌:BIOFINE
種屬:大鼠ELISA試劑盒
檢測波長:450nm
所需樣本體積: 50-100ul
適用范圍:僅供科研
保存及有效期:2-8℃，六個月，-20℃一年
檢測目的:用于測定血清，血漿及相關液體毛細血管擴張性共濟失調突變基因(ATM)含量。適合檢測包括血清、血漿、尿液、胸腹水、灌洗液、腦脊液、細胞培養上清、組織勻漿等標本。
contains the standard concentration of analyte will be prepared. Unknowns that generate a signal that is stronger than the known sample are "positive." Those that generate weaker signal are "negative." Doctor Dennis E Bidwell and Alister Voller created the test. History Before the development of the ELISA, the only option for conducting an immunoassay was radioimmunoassay, a technique using radioactively-labeled antigens or antibodies. In radioimmunoassay, the radioactivity provides the signal, which indicates whether a specific antigen or antibody is present in the sample. Radioimmunoassay was first described in a paper by Rosalyn Sussman Yalow and Solomon Berson published in 1960.[5] Because radioactivity poses a potential health threat, a safer alternative was sought. A suitable alternative to radioimmunoassay would substitute a non-radioactive signal in place of the radioactive signal. When enzymes (such as peroxidase) react with appropriate substrates (such as ABTS or 3,3’,5,5’-Tetramethylbenzidine), a change in color occurs, which is used as a signal. However, the signal has to be associated with the presence of antibody or antigen, which is why the enzyme has to be linked to an appropriate antibody. This linking process was independently developed by Stratis Avrameas and G.B. Pierce.[6] Since it is necessary to remove any unbound antibody or antigen by washing, the antibody or antigen has to be fixed to the surface of the container; i.e., the immunosorbent has to be prepared. A technique to accomplish this was published by Wide and Jerker Porath in 1966.[7] In 1971, Peter Perlmann and Eva Engvall at Stockholm University in Sweden, and Anton Schuurs and Bauke van Weemen in The Netherlands independently published papers that synthesized this knowledge into methods to perform EIA/ELISA.[8][9]
毛細血管擴張性共濟失調突變基因(ATM)重鏈和輕鏈的N端的氨基酸排列順序因各種抗體而異，稱為可變區，分別用VH和VL表示。兩者構成抗體的抗原結合部位，只與相應的抗原決定簇匹配，發生特異性結合（見圖），是抗體專一性結合抗原的結構基礎。 IgG可被木瓜蛋白酶分解為三個區段，其中兩個相同的區段稱抗原結合片段（Fab）。每個Fab都保存結合抗原的能力，但只有一個抗原結合位點，是單價的，與抗原結合后不出現凝集或沉淀。另一區段稱Fc段，無抗體活性，但具有IgG*的抗原性。 IgG可被*分解為兩個片段，一個Fab雙體，稱F（ab'）2，能和兩個相同的抗原結合
毛細血管擴張性共濟失調突變基因(ATM)
抗α干擾素抗體(IFNα-Ab)
瘦素(LEP)
骨髓抑制因子1(MPIF-1/CCL23)
抗滋養膜細胞抗體(ATA)
*腺嘌呤二核苷酸磷酸(NADPH)
補體片段3b受體(C3bR)
基膜聚糖/內腔蛋白(LUM)
腫瘤特異生長因子/腫瘤相關因子(TKGF)
膽酸(CA)
生長激素釋放因子(GH-RF)
大腸菌素(colicin)
神經調節蛋白1(NRG-1)
您感興趣的產品PRODUCTS YOU ARE INTERESTED IN
智慧城市網 設計制作，未經允許翻錄必究 .? ? ?
請輸入賬號
請輸入密碼
請輸驗證碼
